Clinical Research Directory

Inclusion Criteria: 1. Age ≥ 18 years with non-valvular atrial fibrillation (NVAF). 2. High stroke risk: CHA2DS2-VASc score ≥ 2 (Male) or ≥ 3 (Female) AND meeting any of the following: 1. Documented history of bleeding (\> 6 months ago) or bleeding tendency (e.g., gingival, nasal, GI, urinary tract, cerebral hemorrhage). 2. Intolerance or unwillingness to undergo long-term anticoagulation therapy. 3. Recurrent stroke or embolic events despite standardized anticoagulation. 4. Predicted high bleeding risk (HAS-BLED score ≥ 3). 5. Status post-Left Atrial Appendage Electrical Isolation (LAAEI). 3. Subject or legal representative understands the study purpose, is willing to cooperate with surgery and follow-up, and has signed the written Informed Consent Form (ICF). Exclusion Criteria: 1. Rheumatic heart disease, moderate-to-severe mitral stenosis/regurgitation, severe aortic valve disease, or severe LVOT obstruction (gradient \> 40 mmHg). 2. Left ventricular ejection fraction (LVEF) \< 30%. 3. Complex LAA anatomy unsuitable for LAAO implantation. 4. Pericardial effusion \> 10mm. 5. Planned ablation or cardioversion post-procedure. 6. Intracardiac thrombus (including left/right atrium). 7. Myocardial infarction within the last 3 months. 8. History of ASD repair or PFO occluder implantation. 9. History of heart valve replacement (mechanical valve). 10. Heart transplant recipient. 11. New-onset ischemic stroke or TIA within the last 30 days. 12. Severe heart failure (NYHA Class IV). 13. Severe renal impairment: eGFR \< 45 ml/min/1.73m² or on dialysis. 14. Hypersensitivity or contraindication to aspirin, clopidogrel, heparin, contrast media, or nitinol. 15. Pregnant or lactating women, or those planning pregnancy within one year. 16. Life expectancy \< 12 months. 17. Unable to complete 2 months of anticoagulation or 6 months of DAPT for any reason. 18. Investigator's judgment of poor compliance or inability to complete the study requirements.